Skip to main content
S

SICHUAN HEBANG BIOTECHNOLOGY CO.,LTD. — Investor Relations & Filings

Ticker · 603077 LEI · 30030072W72E4N589G74 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,738 across all filing types
Latest filing 2026-04-20 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603077

About SICHUAN HEBANG BIOTECHNOLOGY CO.,LTD.

Sichuan Hebang Biotechnology Co., Ltd. specializes in the manufacturing and distribution of chemical products, agrochemicals, and advanced materials. The company leverages extensive salt and phosphate mineral resources to produce a diverse portfolio, including soda ash and ammonium chloride for industrial and agricultural applications. A significant portion of its operations is dedicated to the production of glyphosate, a broad-spectrum herbicide, and methionine, an essential amino acid for animal nutrition. Additionally, the company has expanded into the new energy sector, producing high-performance glass products such as float glass and photovoltaic glass. By integrating resource extraction with downstream chemical processing, the company maintains a vertically integrated supply chain, serving global markets in the chemical, agricultural, and renewable energy sectors.

Recent filings

Filing Released Lang Actions
首创证券股份有限公司关于和邦生物2024年度向不特定对象发行可转债之保荐总结报告书
Capital/Financing Update Classification · 1% confidence The document is a detailed “保荐总结报告书” issued by the sponsor (首创证券) summarizing its due diligence and continuous supervision duties for Sichuan Hebang’s 2024 convertible bond issuance. It is not an annual or interim financial report, earnings release, voting or board change notice, or dividend/ESG disclosure, but rather a full financing update surrounding the issuance of convertible bonds (a debt/equity hybrid fundraising activity). Under our taxonomy, this falls squarely under “Capital/Financing Update” (CAP).
2026-04-20 Chinese
首创证券股份有限公司关于和邦生物2025年度持续督导工作现场检查报告
Audit Report / Information Classification · 1% confidence The document is a detailed onsite inspection report prepared by the sponsor (首创证券) under the Shanghai Stock Exchange’s continuing supervision rules. It is not a standard financial results release, annual report, or simple announcement, but rather a standalone compliance/audit-style inspection report. This aligns with the “Audit Report / Information” category (AR).
2026-04-20 Chinese
和邦生物独立董事胡杨2025年度述职报告
Governance Information Classification · 1% confidence The document is not an earnings release, financial report, or announcement of a manager change. It is an annual performance report (“述职报告”) prepared by the independent director describing governance duties, board attendance, review of related party transactions, internal controls, and compliance with governance codes. This clearly falls under Governance Information, which covers detailed disclosures of board practices, structures, and governance compliance.
2026-04-20 Chinese
首创证券股份有限公司关于和邦生物向不特定对象发行可转债之2025年度持续督导年度报告书
Regulatory Filings Classification · 1% confidence The document is a full “持续督导年度报告书” (continuous supervision annual report) prepared by the sponsor (保荐机构) for the issuance of convertible bonds. This is neither an earnings release nor an annual report, nor any of the specialized categories like M&A, dividend notice, board changes, or financial supplements. It is a regulatory‐type filing required by the CSRC and Shanghai Stock Exchange, and does not neatly fit other categories. Hence it falls under the fallback “Regulatory Filings” category (RNS).
2026-04-20 Chinese
和邦生物日常关联交易公告
Regulatory Filings Classification · 1% confidence The document is an exchange announcement titled “日常关联交易公告” describing the company’s ordinary related‐party transactions, approval procedures, amounts, counterparties, and pricing policies. It is not a financial report (10‐K, IR), not a proxy or voting results, not an earnings release, not an investor presentation, nor a share or dividend notice. It is a routine regulatory disclosure of related‐party transactions required by the exchange, fitting the catch‐all category for general regulatory filings. Therefore, the correct classification is RNS (Regulatory Filings).
2026-04-20 Chinese
和邦生物2026年一季度主要经营数据公告
Regulatory Filings Classification · 1% confidence The document is a short regulatory announcement disclosing the company’s 2026 Q1 major operating data (production volumes, sales volumes, revenues, and price changes) in compliance with Shanghai Stock Exchange industry‐specific disclosure guidelines. It does not present full financial statements like a formal quarterly (interim) report, nor is it merely an announcement that a report is available. It is a direct regulatory filing reporting operating metrics, fitting the general ‘Regulatory Filings’ category.
2026-04-20 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.